Nektar Therapeutics (NKTR) to Release Earnings on Tuesday
Nektar Therapeutics (NASDAQ:NKTR) will be posting its quarterly earnings results after the market closes on Tuesday, November 7th. Analysts expect Nektar Therapeutics to post earnings of $0.21 per share for the quarter.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The business had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. During the same period in the previous year, the business posted ($0.36) earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, analysts expect Nektar Therapeutics to post $-0.95 EPS for the current fiscal year and $-1.18 EPS for the next fiscal year.
Shares of Nektar Therapeutics (NKTR) traded down 0.71% during mid-day trading on Wednesday, reaching $23.92. The company’s stock had a trading volume of 71,638 shares. The company’s 50 day moving average price is $23.37 and its 200-day moving average price is $20.68. The company’s market capitalization is $3.74 billion. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $25.02.
Several research firms have issued reports on NKTR. Jefferies Group LLC reiterated a “buy” rating and set a $23.00 target price on shares of Nektar Therapeutics in a research report on Friday, August 18th. BidaskClub upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. HC Wainwright began coverage on Nektar Therapeutics in a research report on Monday, August 7th. They set a “buy” rating and a $31.00 target price on the stock. Zacks Investment Research cut Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Finally, William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $26.80.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/01/nektar-therapeutics-nktr-to-release-earnings-on-tuesday.html.
In other Nektar Therapeutics news, SVP Stephen K. Doberstein sold 43,677 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $24.97, for a total transaction of $1,090,614.69. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Roy A. Whitfield purchased 35,000 shares of Nektar Therapeutics stock in a transaction on Thursday, August 10th. The shares were acquired at an average cost of $17.95 per share, for a total transaction of $628,250.00. Following the purchase, the director now owns 133,000 shares in the company, valued at $2,387,350. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 539,983 shares of company stock worth $12,388,528. 5.44% of the stock is owned by insiders.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.